Four years ago, Boehringer Ingelheim agreed to pay roughly $650 million to settle claims that its blood thinner Pradaxa caused excessive bleeding. But when the pharmaceutical giant was hit with a new wave of Pradaxa suits, Boehringer changed course. This time, it decided to go to court and fight.

The company turned to Covington & Burling’s Phyllis Jones, who has racked up a series of wins on behalf of drug companies facing product liability suits, including Eli Lilly and Co.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at c[email protected]